Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
COPD & the eye: Ocular microstructures affected by chronic disease
November 7th 2022In both patients and controls, investigators measured retinal nerve fiber layer thickness, foveal avascular zone area, and vessel density in the superficial capillary plexus, deep capillary plexus, and radial peripapillary capillary plexus.
Read More
Timing is everything with early treatment of AMD
November 3rd 2022In a real-world setting, eyes with AMD with a relatively good initial best-corrected visual acuity and no fibrovascular pigment epithelial detachment sustained or improved BCVA after anti-VEGF therapy within 3 years of follow-up.
Read More
Sailing study and extension study: Superiority of conbercept over laser in DME
November 1st 2022The Sailing study was a 12-month, 18-center, randomized, double-masked, double-sham, parallel-controlled, phase 3 trial that was conducted in China and included eyes with center-involved DME that were randomly assigned to undergo either laser photocoagulation followed by as-needed sham intravitreal injections or sham laser photocoagulation followed by as-needed 0.5 mg intravitreal injections of conbercept.
Read More
Cataract surgery in RP patients yield marked improvements in BCVA
October 29th 2022In this retrospective, non-comparative clinical study, the investigators evaluated the preoperative, intraoperative, and postoperative data of the 225 study patients (295 eyes; mean patient age, 56.1 years) collected from several European centers.
Read More
Association between BMI and retinal structural changes investigated
October 19th 2022In this cross-sectional study, investigators used OCTA to identify possible associations between body mass index and the waist-to-hip ratio with macular vessel density and foveal avascular zone in healthy Chinese adults.
Read More
Ranibizumab recall: Genentech recalls ocular implant in the US
October 18th 2022The company noted that testing of a commercial supply of the implants, which included exposing them to multiple punctures with a needle, found they did not meet their standards. The company has notified the FDA, and is working with the agency on the recall process.
Read More
Retinal nerve fiber layer thinning associated with the degree of smoking in patients with POAG
October 17th 2022Investigators conducted a longitudinal study of the relationship between smoking and smoking intensity and the rate with which the retinal nerve fiber layer becomes thinner in patients with primary open-angle glaucoma.
Read More
No significant association found between anti-VEGF therapy for ROP and pulmonary hypertension
October 15th 2022Anti-VEGF therapy for ROP has potential ocular and systemic advantages compared with laser but also noted that the systemic risks of anti-VEGF therapy in these infants need to be quantified.
Read More
Risk of rhegmatogenous retinal detachment rises following cataract surgery
October 4th 2022The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Read More
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Read More
Continuous range-of-motion IOL scores high in patient satisfaction
September 30th 2022Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
Read More
Study finds ranibizumab biosimilar equivalent in safety, efficacy for the treatment of wet AMD
September 25th 2022The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the ranibizumab and biosimilar treatment groups.
Read More